• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.

作者信息

Maiti Abhishek, Rausch Caitlin R, Cortes Jorge E, Pemmaraju Naveen, Daver Naval G, Ravandi Farhad, Garcia-Manero Guillermo, Borthakur Gautam, Naqvi Kiran, Ohanian Maro, Short Nicholas J, Alvarado Yesid, Kadia Tapan M, Takahashi Koichi, Yilmaz Musa, Jain Nitin, Kornblau Steven, Montalban Bravo Guillermo, Sasaki Koji, Andreeff Michael, Bose Prithiviraj, Ferrajoli Alessandra, Issa Ghayas C, Jabbour Elias J, Masarova Lucia, Thompson Philip A, Wang Sa, Konoplev Sergej, Pierce Sherry A, Ning Jing, Qiao Wei, Welch John S, Kantarjian Hagop M, DiNardo Courtney D, Konopleva Marina Y

机构信息

Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, USA.

Division of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, USA.

出版信息

Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.

DOI:10.3324/haematol.2020.252569
PMID:32499238
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927994/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b3d/7927994/5de11d84b561/106894.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b3d/7927994/33600b4e4224/106894.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b3d/7927994/5de11d84b561/106894.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b3d/7927994/33600b4e4224/106894.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6b3d/7927994/5de11d84b561/106894.fig2.jpg

相似文献

1
Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens.一线使用去甲基化药物和维奈克拉方案治疗后复发或难治性急性髓系白血病的疗效
Haematologica. 2021 Mar 1;106(3):894-898. doi: 10.3324/haematol.2020.252569.
2
Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.复发或难治性急性髓系白血病成人患者中，去甲基化药物/维奈克拉与强化化疗的比较
Br J Haematol. 2022 Aug;198(3):e35-e37. doi: 10.1111/bjh.18229. Epub 2022 May 4.
3
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).维奈托克与低甲基化药物（HMA）用于新诊断、复发或难治性KMT2A重排急性髓系白血病（AML）患者的临床经验
Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.
4
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.一线维奈托克联合低甲基化药物治疗失败后急性髓系白血病患者的预后
Haematologica. 2023 Nov 1;108(11):3170-3174. doi: 10.3324/haematol.2022.282677.
5
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.在未经治疗的老年急性髓系白血病患者中，venetoclax 联合地西他滨或阿扎胞苷的安全性和初步疗效：一项非随机、开放标签、1b 期研究。
Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.
6
Venetoclax in acute myeloid leukemia - current and future directions.维奈托克治疗急性髓系白血病——现状与未来方向。
Leuk Lymphoma. 2020 Jun;61(6):1313-1322. doi: 10.1080/10428194.2020.1719098. Epub 2020 Feb 7.
7
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.初治急性髓系白血病中对维奈托克加去甲基化药物反应的分子预测指标
Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214.
8
Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.维奈托克单药治疗以及联合去甲基化药物或低剂量阿糖胞苷用于复发和难治性急性髓系白血病的系统评价和荟萃分析
Haematologica. 2020 Nov 1;105(11):2659-2663. doi: 10.3324/haematol.2019.242826.
9
Venetoclax in Combination with Hypomethylating Agents for the Treatment of Treatment-Naive B/Myeloid Mixed-Phenotype Acute Leukemia and Relapsed/Refractory Acute Myeloid Leukemia: A Report of 3 Cases.维奈托克联合低甲基化药物治疗初治 B/髓系混合表型急性白血病和复发/难治性急性髓系白血病：3 例报告。
Chemotherapy. 2022;67(3):178-182. doi: 10.1159/000519882. Epub 2022 Mar 18.
10
Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent.克拉屈滨加阿糖胞苷加维奈克拉治疗对维奈克拉加去甲基化药物难治或复发的急性髓系白血病
Haematologica. 2024 Aug 1;109(8):2706-2710. doi: 10.3324/haematol.2024.284962.

引用本文的文献

1
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.口服CDK9抑制剂沃鲁西利与维奈克拉联合用于复发/难治性急性髓系白血病患者。
Blood Neoplasia. 2025 Apr 25;2(3):100108. doi: 10.1016/j.bneo.2025.100108. eCollection 2025 Aug.
2
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.复发/难治性急性髓系白血病患者接受维奈托克联合去甲基化药物治疗时，缓解时间是否会影响治疗结果？一项单中心观察性研究的概念验证。
J Clin Med. 2025 Aug 7;14(15):5586. doi: 10.3390/jcm14155586.
3

本文引用的文献

1
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.一线 venetoclax 联合治疗老年 AML 患者后的反应和治疗失败的分子模式。
Blood. 2020 Mar 12;135(11):791-803. doi: 10.1182/blood.2019003988.
2
Targeting transcription factors in cancer - from undruggable to reality.靶向癌症转录因子——从不可成药到现实。
Nat Rev Cancer. 2019 Nov;19(11):611-624. doi: 10.1038/s41568-019-0196-7. Epub 2019 Sep 11.
3
Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies.
Phase I first-in-human dose escalation study of the oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 in advanced MDS and AML.
口服酪蛋白激酶1α和细胞周期蛋白依赖性激酶7/9抑制剂BTX A51用于晚期骨髓增生异常综合征和急性髓系白血病的I期首次人体剂量递增研究。
J Hematol Oncol. 2025 Jul 15;18(1):73. doi: 10.1186/s13045-025-01724-z.
4
A structure-based modelling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia.一种基于结构的建模方法可识别出针对RAS突变型急性髓系白血病的有效联合用药方案。
bioRxiv. 2025 May 3:2025.04.29.651188. doi: 10.1101/2025.04.29.651188.
5
[Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy].塞利尼索联合皮下注射地西他滨治疗对维奈克拉治疗难治或复发的髓系恶性肿瘤的疗效
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):473-477. doi: 10.3760/cma.j.cn121090-20240920-00358.
6
Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia.在成人急性髓系白血病中，使用去甲基化药物和维奈托克后进行强化化疗。
Blood Neoplasia. 2024 Aug 28;1(4):100038. doi: 10.1016/j.bneo.2024.100038. eCollection 2024 Dec.
7
Allogeneic Transplantation for Older Adults.老年人的异体移植
Adv Exp Med Biol. 2025;1475:9-40. doi: 10.1007/978-3-031-84988-6_2.
8
Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study.维奈克拉与阿扎胞苷在中国治疗急性髓系白血病的疗效及安全性：一项真实世界单中心研究
BMC Cancer. 2025 Jun 3;25(1):990. doi: 10.1186/s12885-025-14167-z.
9
Unraveling Venetoclax Resistance: Navigating the Future of HMA/Venetoclax-Refractory AML in the Molecular Era.解析维奈托克耐药性：在分子时代探索HMA/维奈托克难治性急性髓系白血病的未来。
Cancers (Basel). 2025 May 7;17(9):1586. doi: 10.3390/cancers17091586.
10
(R)-WAC-224, a new anticancer quinolone, combined with venetoclax and azacitidine overcomes venetoclax-resistant AML through MCL-1 downregulation.(R)-WAC-224，一种新型抗癌喹诺酮类药物，与维奈克拉和阿扎胞苷联合使用，通过下调MCL-1克服维奈克拉耐药的急性髓系白血病。
Sci Rep. 2025 May 8;15(1):16018. doi: 10.1038/s41598-025-98534-7.
剪接体基因的突变与髓系恶性肿瘤的治疗机会。
Genes Chromosomes Cancer. 2019 Dec;58(12):889-902. doi: 10.1002/gcc.22784. Epub 2019 Sep 3.
4
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.TP53 凋亡网络是 AML 细胞中对 BCL2 抑制产生耐药的主要介质。
Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2.
5
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
6
Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).在早期临床试验中研究的 BET 溴结构域蛋白抑制剂治疗急性髓系白血病 (AML)。
Expert Opin Investig Drugs. 2017 Jul;26(7):803-811. doi: 10.1080/13543784.2017.1335711. Epub 2017 Jun 9.
7
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience.老年急性髓系白血病患者一线治疗失败后使用去甲基化药物的结果：单机构经验。
Am J Hematol. 2017 Sep;92(9):866-871. doi: 10.1002/ajh.24780. Epub 2017 Jun 5.
8
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.老年急性髓系白血病具有独特的基因和表观遗传特征。
Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3.
9
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.成人急性髓系白血病的诊断与管理：2017年国际专家小组的欧洲白血病网络（ELN）建议
Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28.
10
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.